⌘K
t
| Date | 18 Aug 2021 |
| Time | 12:09:06 |
| Category | Director/PDMR dealings |
| ID | 0540J |
Director Dealings
Guildford, UK - 18 August 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that on 17 August 2021, in order to meet demand from new and existing investors, Dr Miroslav Reljanović, Executive Chairman of Ergomed, and Richard Barfield, Chief Financial Officer of Ergomed, sold 1,200,000 ordinary shares of 1p each in the Company ("Ordinary Shares") and 50,000 Ordinary Shares respectively at a price of 1200 pence per share.
Following these sales, Dr Miroslav Reljanović holds 9,679,297 Ordinary Shares representing 19.8% of the Company's issued share capital and Richard Barfield holds 50,000 Ordinary Shares representing 0.1% of the Company's issued share capital.
The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Dr Miroslav Reljanović |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Executive Chairman |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Ergomed plc |
|
|
b) |
Legal Entity Identifier |
213800BVS8I9VMC1AP84 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 1 pence each
GB00BN7ZCY67 |
|
|
b) |
Nature of the transaction |
Sale of Shares |
|
|
c) |
Currency |
GBP |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£12.00 |
1,200,000 |
||
|
|
|
||
|
e) |
Aggregated information
- Aggregated volume
- Price
- Aggregated total |
1,200,000
£12.00
£14,400,000
|
|
|
f) |
Date of the transaction |
17 August 2021 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Richard Barfield |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Financial Officer |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Ergomed plc |
|
|
b) |
Legal Entity Identifier |
213800BVS8I9VMC1AP84 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 1 pence each
GB00BN7ZCY67 |
|
|
b) |
Nature of the transaction |
Sale of Shares |
|
|
c) |
Currency |
GBP |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£12.00 |
50,000 |
||
|
|
|
||
|
e) |
Aggregated information
- Aggregated volume
- Price
- Aggregated total |
50,000
£12.00
£600,000
|
|
|
f) |
Date of the transaction |
17 August 2021 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr. Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com.